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ensuring that the SB postdilation balloon is the same diameter or
larger than the deploying balloon (2).
In addition, Colombo (3) has described the importance of
performing “before kissing, a high-pressure balloon inflation in the
side-branch so as to be sure to expand the stent fully at the ostium.”
Costa et al. (1) also found that “incomplete stent apposition in the
crush area was common.” Some operators deliberately undersize
the main vessel (MV) balloon during kissing inflation to avoid
“oversizing” by the double balloons at the proximal end of the MV
stent. We have previously shown that this leads to MV stent
distortion (2,4) and incomplete crushing (2) and that these
outcomes can be prevented or repaired by kissing with appropri-
ately sized balloons in the MV and SB.
Finally, it is not clear whether Costa et al. (1): 1) performed a
separate high-pressure inflation in the SB before kissing; 2)
whether the MV and SB balloons were smaller, the same size, or
larger than the deploying balloons (the reported stent and final
balloon diameters are a mean of the study population); and 3) what
pressures were achieved in the SB and MV balloons during kissing
inflations. This information is particularly pertinent for those cases in
which the MSA of the SB ostium was 4 mm2 and when
incomplete crushing was observed.
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REPLY
The investigators of the referenced study (1) thank McNab and
colleagues for their comments. Regarding questions about the
procedural “steps” and final kissing balloon (KB) inflation among
non-left main lesions (n  20) treated with sirolimus-eluting stent
(SES) crush stenting and final intravascular ultrasound (IVUS) in
both branches, the responses are as follows:
1. Only 40% (8 of 20 patients) had a separate high-pressure
inflation (12 atm) in the side branch (SB) before KB;
2. final KB inflation (90%) was performed in the main vessel
(MV) with a balloon of the same size as the “deployment”
balloon in 89% (16 of 18 patients), with a smaller balloon in
5.6% (1 of 18 patients), and with a larger balloon in 5.6% (1 of
18 patients);
3. final KB inflation was performed in the SB using a same-size
balloon (same as “deployment” balloon) in all but one case,
94.4% (17 of 18 patients); in one case a smaller balloon was
used;
4. the pressure of the KB inflation was 10.4 4.1 atm in the MV
and 14.3  3.8 atm in the SB.
When we consider these analyses in lesions with minimum stent
area (MSA) at the SB ostium 4 mm2 versus MSA 4 mm2, we
found:
1. similar rates of high-pressure balloon inflation in the SB prior
to KB (42% vs. 38%, p  0.8);
2. balloon pressure at the SB during KB was 14.6  3.8 atm (4
mm2) versus 15.6  2.8 atm (4 mm2), p  0.6.
In addition, a comparison of lesions with incomplete crush (IC)
versus “complete” crush (CC) showed that:
1. 33% of lesions with IC had SB high-pressure inflation before
KB versus 25% of lesions with CC, p  0.6;
2. IC had lower balloon pressure during KB in the SB (12.3 
3.7 atm for IC vs. 17  3.8 atm for CC; p  0.04).
Finally, we could not demonstrate any impact of high-pressure
balloon inflation in the SB before KB on final luminal dimensions
in the SB and on the incidence of IC; this may be due to the small
sample size. However, these results showed that higher balloon
pressures in the SB during KB inflation are associated with
complete “crush” stent apposition, indicating that IC is associated
with SB stent underexpansion (1).
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Secondary Stroke
Prevention and Antiplatelet Therapy
A truth that’s told with bad intent beats all the lies you can invent
—William Blake (1757–1827, Auguries of Innocence)
I was very disappointed to see JACC publish an opinion piece by
Dr. Gebel that is basically a cleverly disguised advertisement for
Aggrenox (1). Extended-release dipyridamole (ER-DP) and aspi-
rin is sold as Aggrenox, which is made by Boehringer Ingelheim,
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which (as he disclosed) gives speaker bureau support and clinical
research support to Dr. Gebel.
Consider my representative patient recently admitted to the
hospital with a transient ischemic attak (TIA) shortly after
drug-eluting stent implantation for in-stent restenosis. The neu-
rologist and internist stopped his aspirin and clopidogrel and put
him on Aggrenox. The patient thought this sounded wrong, and
he asked them to check with me but they did not. Fortunately, I
walked into the patient’s room to do a consult on his roommate,
discovered the error, corrected it, and the patient did well.
However, if my patient had been in a private room, if I had not
been on consult, if no cardiology consult had been ordered on his
roommate, or if my patient had been out of the room when I
arrived, he could have developed subacute stent thrombosis with its
associated 50% mortality rate. But for an extremely lucky series of
coincidences my patient could have died.
When I asked the other physicians why they did this, one stated
that the Management of Atherothrombosis in High-risk Patients
with Recent Transient Ischemic Attack or Ischemic Stroke
(MATCH) trial showed that Aggrenox was better than clopi-
dogrel for prevention of stroke and presented handouts from a
recent talk that had clearly been sponsored by the makers of
Aggrenox (directly or indirectly). The handouts bore a striking
resemblance to Dr. Gebel’s opinion piece. As we know, the
MATCH trial did not include Aggrenox, but compared acetyl-
salicylic acid (ASA) to clopidogrel or clopidogrel plus aspirin (2).
Interestingly, whether by oversight or for purposes of obfuscation, the
50-mg subtherapeutic aspirin dose in the Second European Stroke
Prevention Study (ESPS-2) is not mentioned either in Dr. Gebel’s
report (1) or in the talk handout. The clever design of the presentation
leads the listener to believe Aggrenox has done the appropriate
research to compare itself to clopidogrel or therapeutic doses of aspirin
to demonstrate efficacy and safety in cardiovascular patients; it has not.
The widely cited ESPS-2 trial compared Aggrenox to 50 mg of
aspirin daily; 50 mg of aspirin daily is not a therapeutic dose. In the
Antithrombotic Trialists’ meta-analysis, no benefit was seen of
aspirin over placebo with doses of aspirin 75 mg daily (3). In the
Women’s Health Study, no benefit was seen of aspirin 100 mg
every other day compared to placebo (4). These results suggest that
the majority of the benefit seen in the ESPS-2 trial was due to
subtherapeutic aspirin dosing, not to a dramatic benefit of Ag-
grenox. Even with this subtherapeutic dosing, aspirin had a 21%
relative risk reduction (RRR) in myocardial infarctions. One would
expect a greater RRR with therapeutic aspirin dosing.
Tran and Anand published a balanced review of this topic in
2004 (5). Their recommendation, based on viable therapeutic
alternatives, prior adverse experiences with dipyridamole, and only
a single clinical trial showing benefit of Aggrenox (in which it was
compared to subtherapeutic doses of aspirin), is that Aggrenox
should be avoided until data are available from ongoing clinical trials.
At last year’s cardiology meetings, there were multiple reports in
verbal presentations of drug-eluting stent thrombosis in patients
being treated with aspirin and dipyridamole. The implication was
that these were non-U.S. patients. Under these circumstances,
these data would not be reported to the Food and Drug Admin-
istration (FDA). Given the aggressive marketing campaign being
run by Boehringer Ingelheim, cardiologists must be very vigilant in
protecting their patients. Perhaps the FDA could withdraw Ag-
grenox from the market until it has shown superiority, equivalence,
or noninferiority to therapeutic doses of aspirin (75 mg daily, or
preferably 81 mg as is used in U.S. practice). Perhaps the FDA
could do a black box warning and letter against its use in coronary
stent patients. Perhaps individual institutions can remove it from
their formularies or place it on restricted formularies so that a
cardiologist, not a neurologist or primary care physician, must
review each case to limit the potential for harm in withdrawal of
effective antiplatelet therapy in high-risk patients.
Finally, this issue is likely to be more critical now that Aggrenox
representatives will be carrying around copies of this opinion piece,
and the neurologists and primary care providers will say that they
read a study in JACC stating that “clinical trial data support the use
of ER-DP plus aspirin [Aggrenox], but not clopidogrel plus
aspirin, to prevent secondary vascular events after stroke of TIA”
(1). Unfortunately, this is because the appropriately designed trials
have not been done, not because Aggrenox has documented
superiority, equivalence, or even noninferiority to any other ther-
apeutic antiplatelet regimen.
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REPLY
Stick to the obvious.
—Dennis Whitehead (my 11th-grade biology teacher)
It was with surprise and disappointment that I read the “letter” to
the editor authored by Dr. Horton.
If I am interpreting Dr. Horton’s missive correctly, the follow-
ing summarize her major points of concern or contention, which I
will respond to respectively:
1. It is inappropriate to withdraw aspirin plus clopidogrel therapy in
patients in the periprocedural period following coronary artery
stent placement, even if they suffer a periprocedural stroke/transient
ischemic attack (TIA). My report (1) was not intended to
comment on the appropriate use of antiplatelet medications in
patients undergoing recent coronary artery angioplasty and
stenting, or patients with acute coronary syndromes, for whom
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